Viridian Therapeutics, Inc. (VRDN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Viridian Therapeutics, Inc. (VRDN) is down 47.5% since the beginning of the year. At $16 per share, VRDN is trading 52.3% below its 52-week high of $34. Investors who bought $1,000 worth of VRDN shares 5 years ago would now be looking at an investment worth $1,019.

Viridian Therapeutics, Inc. (VRDN) has returned -47.46% so far this year and 13.15% over the past 12 months. Over the last ten years, VRDN has returned -18.47% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Jun 18, 2014, VRDN's average daily return is +0.08%, while the average monthly return is +0.29%. At this rate, an investment would double in approximately 19.9 years.

Historically, 40% of months were positive and 60% were negative. The best month was Jan 2020 with a return of +264.6%, while the worst month was Feb 2020 at -57.5%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 8 months.

On a daily basis, VRDN closed higher 44% of trading days. The best single day was Jan 10, 2017 with a return of +264.9%, while the worst single day was Feb 7, 2020 at -37.9%.

Viridian Therapeutics, Inc. has an annualized alpha of 9.49%, beta of 0.80, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 19, 2014.

• This stock participated in 182.66% of S&P 500 Index downside but only -15.54% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VRDN ranks 49 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Viridian Therapeutics, Inc. (VRDN) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Viridian Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Viridian Therapeutics, Inc. was 99.73%, occurring on Mar 19, 2020. The portfolio has not yet recovered.

The current Viridian Therapeutics, Inc. drawdown is 99.20%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Viridian Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Viridian Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.